This article is more than 5 years old. Information may no longer be current.
Myopic astigmatism can be treated with toric phakic IOL
Click Here to Manage Email Alerts
Implantation of an iris-fixated toric phakic IOL in patients with myopic astigmatism can result in effective, predictable, safe and stable outcomes, according to a study.
The prospective, nonrandomized, interventional cohort study enrolled 42 eyes of 25 patients between the ages of 21 and 39 years who had the Artiflex toric phakic IOL (Ophtec) implanted for the correction of myopic astigmatism.
The researchers evaluated refraction, uncorrected distance visual acuity, corrected distance visual acuity, complications, phakic IOL misalignment and endothelial cell count at 12 months.
Mean spherical equivalent decreased from –8.85 ± 2.71 D to –0.37 ± 0.46 D; 66.7% of the eyes within ±0.5 D of emmetropia, the study found. Mean cylinder power decreased from –2.9 D (range: –1.5 to –5 D) to –0.39 D (range: 0 D to –1.5 D), and refraction was stable.
All eyes had uncorrected distance visual acuity of 0.5 or better and corrected distance visual acuity of 0.8 or better, and 69.1% of eyes gained one or more lines of corrected distance visual acuity. The mean misalignment of the IOL was 2.6 ± 1.8°. The mean decrease in endothelial cell count was 9.3 ± 1.8%.
“Refractive and visual outcomes were very satisfactory and fairly consistent throughout the 12-month follow-up,” the study authors said, noting the need for longer-term studies with larger patient cohorts to assess stability and safety.
Click Here to Manage Email Alerts